Sanjivani Paranteral Ltd — Important, 21-11-2025: Company Update

Sanjivani Paranteral's recent earnings call revealed a dip in revenue and profit for the quarter, primarily due to external disruptions like local unrest in Nepal and tighter export market scrutiny, leading to deferred shipments. Despite this, the company maintains optimism, projecting 10% growth for the current year and around 15-20% for the base business next year. The SPL Infusion (Pune) IV plant has commenced commercial operations, with revenue expected from the current quarter, targeting up to INR 110 crore annually by the second quarter of the next financial year. The Alevia Healthcare nutraceutical venture is also picking up, contributing to the bottom line. Sanjivani is focused on diversification, fast lead times, and stringent quality to mitigate risks and drive future growth.